Previous close | 2.2600 |
Open | 2.2600 |
Bid | 0.0000 |
Ask | 2.8500 |
Strike | 5.00 |
Expiry date | 2024-10-18 |
Day's range | 2.2600 - 2.2600 |
Contract range | N/A |
Volume | |
Open interest | 134 |
BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following event and investor conferences: • Caribou’s webcast of KOL discussion from 2024 American Society of Clinical Oncology (ASCO) Annual MeetingJune 2, 2024, CB-010 ANTLER Phase 1 clinical trial data in r/r B-NHL to be shared in a press release at 6:00 pm CDT followed by a liv
Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders are probably feeling a little disappointed, since its shares...
Caribou Biosciences (CRBU) delivered earnings and revenue surprises of -17.95% and 19.03%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?